Experience

Davis Polk advised the underwriter in connection with the initial public offering of 30,000,000 units of Broadstone Acquisition Corp., for aggregate proceeds of $300 million. Each unit…

Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering of common stock by i3 Verticals, Inc. i3 Verticals, Inc. sold 3,737,500…

Davis Polk advised the representatives of the several underwriters in connection with the follow-on offering of 4,791,665 shares of common stock of Natera, Inc. for total gross…

Davis Polk advised the lead managers on an SEC-registered offering by TD Bank of (i) $1.25 billion aggregate principal amount of its 0.450% senior notes due 2023 and (ii) $1 billion…

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 60,000,000 units of TWC Tech Holdings II Corp., including 7,500,000…

Davis Polk advised the initial purchasers in connection with a $250 million Regulation S only offering by China South City Holdings Limited (“CSC”) of its 10.750% senior notes due 2023…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk advised the underwriters in connection with the initial public offering of 30,000,000 units of Prime Impact Acquisition I, for aggregate proceeds of $300 million. Each unit…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Quicken Loans, LLC of $750 million aggregate principal amount of its…

Davis Polk advised Arco Platform Limited on its SEC-registered follow-on offering of an aggregate of 2,500,000 Class A common shares issued and sold by Arco at a price per Class A common…